AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04800757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group (Group Problem Solving)
Description: Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
Study NCT04800757 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (OSHA 10 Safety Cards)
Description: Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
Study NCT05564338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study NCT05564338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib-matching placebo
Description: administered orally
Study NCT05564338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab-matching placebo
Description: administered intravenously
Study NCT06217250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional EMR
Description: Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.Nevertheless, this technique is associated with the emergence of serious adverse events (SAEs), including delayed bleeding (PPB), electrocautery-induced post-polipectomy syndrome (PPS), and perforation(4).
Study NCT06217250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the cold snare (CO), underwater technique (W), and the use of submucosal lift (L) in both study arms
Description: The cold-EMR technique, as opposed to the conventional approach, employs a specialized snare that enables tissue transection without the need for electrical current, particularly in appropriately selected lesions. This approach yields the same efficacy outcome as the conventional procedure but offers the advantage of reducing the risks associated with polypectomy, which are often secondary to the use of diathermic current. Subsequently, the lesion fragments are retrieved for histological examination. Furthermore, the use of underwater setting, as demonstrated for hot EMR, could improve the effectiveness of cold-EMR.
Study NCT06231017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Cetuximab+ Chemotherapy
Description: Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
Study NCT05657262 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-post test
Description: Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
Study NCT05657262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-post test
Description: Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
Study NCT05657262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental group
Description: The experiment group will be applied with the Z technique.
Study NCT04810273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early progressive mobilization
Description: The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
Study NCT04810273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early progressive mobilization
Description: The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
Study NCT05025943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.
Study NCT05025943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
Study NCT04970329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
Description: Drugs will be given to two group and third group will kept on placebo.
Study NCT04970329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
Description: Drugs will be given to two group and third group will kept on placebo.
Study NCT05898997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
Study NCT06131437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.
Study NCT06131437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously.
Study NCT06131437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide will be administered subcutaneously.
Study NCT04782232 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention due to observational design
Study NCT04789213 — intervention group
Intervention type: OTHER
Intervention: Liver Transplantation
Description: Liver Transplantation
Study NCT04925154 — intervention group
Intervention type: BEHAVIORAL
Intervention: The only intervention will be the information brochure that will be given after the first questionnaire.
Description: The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
Study NCT04910308 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET guided dose painting
Description: The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
Study NCT04839562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 MG
Description: Daily oral consumption
Study NCT04839562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 MG
Description: Daily oral consumption
Study NCT04839562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06038812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GCF sample collection
Description: collecting GCF from deepest sites by paper points
Study NCT05461378 — intervention group
Intervention type: DRUG
Intervention: Evusheld
Description: Participants who have received or plan to receive Evusheld.
Study NCT06030011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NYU Electronic Patient Visit Assessment (ePVA)
Description: The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).
Study NCT06030011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
Study NCT06030011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
Study NCT06335121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER Up strategies -
Description: Clinics will implement adapted POWER Up intervention strategies when a patient is flagged as PrEP eligible.
Study NCT06163079 — intervention group
Intervention type: BEHAVIORAL
Intervention: No intervention
Description: No intervention. This is a retrospective study. Data will be collected from routine consultations Will be collectad the following datas : Number and evolution of requests, age, background, infertility timing, parenthood context, Appointment time, ART timing, Type of ART, ART outcome, Outcome time
Study NCT05340140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: deep learning model
Description: deep learning model developed by computer science expert and based on convolution neural network , and trained by our datasets.
Study NCT05314023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
Study NCT04899908 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Focused radiation beams to treat tumors
Study NCT04899908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX gadolinium-based nanoparticles
Description: Intravenous injection
Study NCT04899908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion
Study NCT05793619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 301) to (816-v1 355) every week
Description: Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05793619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 301) to (816-v1 355) every two weeks
Description: Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT06035107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radar blood pressure device
Description: The radar blood pressure device will be compared with other traditional blood pressure measurement methods.
Study NCT05187949 — intervention group
Intervention type: OTHER
Intervention: Mixed-method approach
Description: Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
Study NCT06038812 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-surgical periodontal treatment
Description: performing scaling and root planning using ultrasonic device and manual curettes
Study NCT05913856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
Study NCT05913856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
Study NCT05656443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171/Ritonavir
Description: dose of 150 mg GST-HG171 with 100 mg ritonavir
Study NCT05656443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04718506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises \[squat, bench press, deadlift and bench pull\]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences
Study NCT04718506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets
Study NCT04718506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controls
Description: Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
Study NCT06378242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin for injection
Description: Intravesical instiliations into the bladder
Study NCT04713137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol
Description: 50g erythritol dissolved in 300mL tap water.
Study NCT04713137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 33.5g sucrose dissolved in 300mL tap water.
Study NCT04713137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucralose
Description: 0.0558g sucralose dissolved in 300mL tap water.
Study NCT04713137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300mL tap water.
Study NCT05317052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage group
Description: Massage and music therapy
Study NCT04971226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Comes in 100 mg and 400 mg tablets and taken orally
Study NCT04971226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Comes in 150 mg capsules and taken orally
Study NCT04971226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib
Description: Comes in 100 mg and 400 mg tablets and taken orally
Study NCT04971226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Comes in 70 mg and 100 mg tablets and taken orally
Study NCT04971226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Comes in 40 mg tablets and taken orally
Study NCT06355622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Characterization of pain
Description: Standardized scales and questionnaires to detect and characterize pain, blood sample for pain biomarkers, neurophysiological tests
Study NCT05792202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfracture procedure
Description: double raw repair combined with microfracture procedure which promotes tendon healing by releasing growth factors
Study NCT05792202 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: only double raw repair
Description: the double raw repair was used to repair the tendon tear
Study NCT04975802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 oz (296 ml) cherry flavored still beverage
Study NCT04975802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffeeberry
Description: 10 oz (296 ml) cherry flavored still beverage
Study NCT04975802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 10 oz (296 ml) cherry flavored still beverage
Study NCT04532788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Customized crosslinking
Description: In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States).
Study NCT04532788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard crosslinking
Description: In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States).
Study NCT05790226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentry System
Description: any labelling or contrast agents. The Sentry System uses the Sentry Probe, a flexible cable that terminates in a stylus that delivers a small beam of light to the surface of the excised tissue specimen and collects the Raman spectrum of the light coming back from the same area of the specimen.
Study NCT06656767 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This study utilises pre-collected samples only.